Clinical trial failure analysis for a disease area — why Phase 2/3 trials failed (wrong target, patient population, endpoint, dose, safety), failure taxonomy with percentages, phase-transition success rates and design lessons. Worldwide. For drug developers and biotech investors.
| Network | Scheme | Amount | Pay To |
|---|---|---|---|
| Base | exact | $0.20 USDC | 0x50ab...12fc |
| solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp | exact | 0.20 tokens | 985iFj...5KX1 |